Literature DB >> 19710147

High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.

Veronica D Gonzalez1, Karolin Falconer, Kim G Blom, Olle Reichard, Birgitte Mørn, Alex Lund Laursen, Nina Weis, Annette Alaeus, Johan K Sandberg.   

Abstract

Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710147      PMCID: PMC2772767          DOI: 10.1128/JVI.01211-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Relation between HIV-1 and hepatitis C viral load in patients with hemophilia.

Authors:  E S Daar; H Lynn; S Donfield; E Gomperts; M W Hilgartner; W K Hoots; D Chernoff; S Arkin; W Y Wong; C A Winkler
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

2.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Authors:  G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

3.  Determinants of the quantity of hepatitis C virus RNA.

Authors:  D L Thomas; J Astemborski; D Vlahov; S A Strathdee; S C Ray; K E Nelson; N Galai; K R Nolt; O Laeyendecker; J A Todd
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

4.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

Authors:  I Bica; B McGovern; R Dhar; D Stone; K McGowan; R Scheib; D R Snydman
Journal:  Clin Infect Dis       Date:  2001-01-23       Impact factor: 9.079

5.  Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs.

Authors:  E S Daar; H Lynn; S Donfield; E Gomperts; S J O'Brien; M W Hilgartner; W K Hoots; D Chernoff; S Arkin; W Y Wong; C A Winkler
Journal:  J Infect Dis       Date:  2001-01-12       Impact factor: 5.226

6.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

7.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.

Authors:  Steven G Deeks; Christina M R Kitchen; Lea Liu; Hua Guo; Ron Gascon; Amy B Narváez; Peter Hunt; Jeffrey N Martin; James O Kahn; Jay Levy; Michael S McGrath; Frederick M Hecht
Journal:  Blood       Date:  2004-04-29       Impact factor: 22.113

8.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

Authors:  Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  Hepatitis C and progression of HIV disease.

Authors:  Mark S Sulkowski; Richard D Moore; Shruti H Mehta; Richard E Chaisson; David L Thomas
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

10.  Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.

Authors:  Veronica D Gonzalez; Karolin Falconer; Jakob Michaëlsson; Markus Moll; Olle Reichard; Annette Alaeus; Johan K Sandberg
Journal:  Clin Immunol       Date:  2008-05-20       Impact factor: 3.969

View more
  63 in total

Review 1.  Immune activation and the role of TLRs and TLR agonists in the pathogenesis of HIV-1 infection in the humanized mouse model.

Authors:  J Judy Chang; Marcus Altfeld
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

Review 2.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 3.  Inflammation, immune activation, and cardiovascular disease in HIV.

Authors:  Eric Nou; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

4.  Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status.

Authors:  Julia L Marcus; Wendy A Leyden; Chun R Chao; Lanfang Xu; Charles P Quesenberry; Phyllis C Tien; Daniel B Klein; William J Towner; Michael A Horberg; Michael J Silverberg
Journal:  AIDS Patient Care STDS       Date:  2015-05-18       Impact factor: 5.078

5.  Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  M K Jain; B Adams-Huet; D Terekhova; L E Kushner; R Bedimo; X Li; M Holodniy
Journal:  J Viral Hepat       Date:  2014-02-09       Impact factor: 3.728

6.  Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.

Authors:  Mark H Kuniholm; Xianhong Xie; Kathryn Anastos; Robert C Kaplan; Xiaonan Xue; Andrea Kovacs; Marion G Peters; Eric C Seaberg; Audrey L French; Mary A Young; Michael Augenbraun; Jeffrey A Martinson; Kristin A Bush; Alan L Landay; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

7.  Immune complexes that contain HIV antigens activate peripheral blood T cells.

Authors:  L B Korolevskaya; K V Shmagel; E V Saidakova; N G Shmagel; V A Chereshnev
Journal:  Dokl Biol Sci       Date:  2016-09-07

8.  Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons.

Authors:  Kara W Chew; Debika Bhattacharya; Kathleen A McGinnis; Tamara B Horwich; Chi-Hong Tseng; Judith S Currier; Adeel A Butt
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-11       Impact factor: 2.205

9.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

10.  High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women.

Authors:  Emmanouil Papasavvas; Lea F Surrey; Deborah K Glencross; Livio Azzoni; Jocelin Joseph; Tanvier Omar; Michael D Feldman; Anna-Lise Williamson; Maureen Siminya; Avril Swarts; Xiangfan Yin; Qin Liu; Cynthia Firnhaber; Luis J Montaner
Journal:  Oncoimmunology       Date:  2016-01-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.